Autolus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Autolus Therapeutics's earnings have been declining at an average annual rate of -13.9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 21.4% per year.
Key information
-13.9%
Earnings growth rate
12.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 21.4% |
| Return on equity | -186.9% |
| Net Margin | -12,272.3% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Autolus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -208 | 47 | 0 |
| 30 Sep 23 | 6 | -158 | 38 | 0 |
| 30 Jun 23 | 7 | -155 | 36 | 0 |
| 31 Mar 23 | 7 | -152 | 33 | 0 |
| 31 Dec 22 | 6 | -149 | 32 | 0 |
| 30 Sep 22 | 3 | -164 | 32 | 0 |
| 30 Jun 22 | 1 | -155 | 32 | 0 |
| 31 Mar 22 | 2 | -146 | 31 | 0 |
| 31 Dec 21 | 2 | -142 | 32 | 0 |
| 30 Sep 21 | 3 | -143 | 33 | 0 |
| 30 Jun 21 | 3 | -147 | 35 | 0 |
| 31 Mar 21 | 2 | -145 | 36 | 0 |
| 31 Dec 20 | 2 | -142 | 35 | 0 |
| 30 Sep 20 | 2 | -140 | 36 | 0 |
| 30 Jun 20 | 1 | -130 | 35 | 0 |
| 31 Mar 20 | 1 | -127 | 38 | 0 |
| 31 Dec 19 | 3 | -124 | 39 | 0 |
| 30 Sep 19 | 3 | -104 | 35 | 0 |
| 30 Jun 19 | 3 | -89 | 35 | 0 |
| 31 Mar 19 | 3 | -68 | 31 | 0 |
| 31 Dec 18 | 1 | -58 | 26 | 0 |
| 30 Sep 18 | 1 | -45 | 23 | 0 |
| 30 Jun 18 | 1 | -41 | 18 | 0 |
| 31 Mar 18 | 2 | -38 | 14 | 18 |
| 31 Dec 17 | 2 | -29 | 12 | 17 |
| 30 Sep 17 | 2 | -20 | 9 | 0 |
| 30 Sep 16 | 1 | -13 | 5 | 0 |
| 30 Sep 15 | 0 | -7 | 6 | 2 |
Quality Earnings: 6A3A is currently unprofitable.
Growing Profit Margin: 6A3A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6A3A is unprofitable, and losses have increased over the past 5 years at a rate of 13.9% per year.
Accelerating Growth: Unable to compare 6A3A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6A3A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 6A3A has a negative Return on Equity (-186.93%), as it is currently unprofitable.